Chronic myeloid leukemia in the Netherlands: a population‐based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012

Thielen, Noortje; Visser, Otto; Ossenkoppele, Gert J.; Janssen, Jeroen

doi:10.1111/ejh.12695

Cited by 36 publications

(44 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As the association between socio‐economic factors and mortality was greater in the control population (assumed to reflect the background mortality), it is unlikely that deaths from other causes could explain the lack of association in patients with CML. It cannot be excluded that the mixture of deaths by CML and other causes could have contributed to our finding of inferior survival in male compared to female patients with CML, a finding contrasting the results from several previous reports . As demonstrated in our control population, men have higher age‐adjusted mortality in general, and a higher rate of non‐CML deaths provides a likely explanation to the association between sex and mortality in patients with CML as well.…”

Section: Discussioncontrasting

confidence: 97%

“…It cannot be excluded that the mixture of deaths by CML and other causes could have contributed to our finding of inferior survival in male compared to female patients with CML, a finding contrasting the results from several previous reports. 8,10,27,28 As demonstrated in our control population, men have higher age-adjusted mortality in general, and a higher rate of non-CML deaths provides a likely explanation to the association between sex and mortality in patients with CML as well.…”

Section: Discussionsupporting

confidence: 66%

See 1 more Smart Citation

The impact of socio‐economic factors on treatment choice and mortality in chronic myeloid leukaemia

Larfors

Sandin

Richter³

et al. 2017

European J of Haematology

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 97%

Section: Discussionsupporting

confidence: 66%

The impact of socio‐economic factors on treatment choice and mortality in chronic myeloid leukaemia

Larfors

Sandin

Richter³

et al. 2017

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…5-year survival ranges around 90%, 10-year survival around 83% and 10year relative survival compared to the general population is more than 90% [2,3]. Similar results have been observed in population based registries [4,5,6]. More patients died of comorbidities than of CML [7].…”

Section: Long Term Survivalsupporting

confidence: 76%

Long-term survival with CML with imatinib or transplantation as first-line treatment: Comparison of outcomes from CML Studies IIIA and IV

Hehlmann¹

2017

CTT

View full text Add to dashboard Cite

With introduction of the tyrosine kinase inhibitor (TKI) imatinib, the treatment strategy of CML has profoundly changed. TKIs became the fi rst-line treatment of choice for CML competing with allogeneic hematopoietic stem cell transplantation (HCT). Variables to be considered in choosing TKIs for fi rst-line therapy are as follows: conventional risk score; cytogenetic fi ndings with major-route additional chromosomal aberrations (ACA) at diagnosis, and high-risk ACA in the course of CML; comorbidities; treatment costs. In cases of refractoriness to imatinib, the 2 nd line treatment options are: clinical response milestones; adherence to therapy; resistance mutations; clonal evolution; therapy intolerance; drug safety; health care setting.CML Study IV, a randomized treatment study concerning imatinib dose optimization and combined therapy with imatinib and cytarabine or interferon α included 1551 newly diagnosed patients in chronic phase. Th e key outcome was no superiority of survival of any treatment option. Imatinib 400 mg provides close to normal life expectancy in chronic-phase CML patients.Survival is independent of time to response. Outcome of CML is currently more determined by disease and patients' factors, e.g., comorbidities and smoking, and by center eff ects than by initial treatment selection. A comparison of long-term survival aft er HCT or imatinib treatment showed that low risk patients had similar survival with both options. Attempts at improving treatment should focus on subgroups of refractory disease e.g. by HCT, and on non-CML determinants of survival. Aft er progression to blast crisis, HCT did not provide a signifi cant survival advantage, although a special study showed that most long-term survivors (72%) were patients who received a transplant. Th e 10-year deep molecular remission rates of 70%-80% indicate that the majority of imatinib-treated patients are candidates for treatment discontinuation.

show abstract

“…The diseases are caused by acquired damage to hematopoetic stem cells 1. The nature of MPNs is a chronic disease course, but mean lifespan is decreased, which is most pronounced in MF patients 2,3. Philadelphia-negative MPNs may change from an early cancer stage (ET and PV) to an advanced cancer stage (MF) with intervening transitional stages 4,5.…”

Section: Introductionmentioning

confidence: 99%

A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents

Brochmann¹,

Flachs²,

Christensen³

et al. 2017

CLEP

View full text Add to dashboard Cite

ObjectiveThe Department of Hematology, Zealand University Hospital, Denmark, and the National Institute of Public Health, University of Southern Denmark, created the first nationwide, population-based, and the most comprehensive cross-sectional health-related quality of life (HRQoL) survey of patients with myeloproliferative neoplasms (MPNs). In Denmark, all MPN patients are treated in public hospitals and treatments received are free of charge for these patients. Therefore, MPN patients receive the best available treatment to the extent of its suitability for them and if they wish to receive the treatment. The aims of this article are to describe the survey design and the characteristics of respondents and nonrespondents.Material and methodsIndividuals with MPN diagnoses registered in the Danish National Patient Register (NPR) were invited to participate. The registers of the Danish Civil Registration System and Statistics Denmark provided information regarding demographics. The survey contained 120 questions: validated patient-reported outcome (PRO) questionnaires and additional questions addressing lifestyle.ResultsA total of 4,704 individuals were registered with MPN diagnoses in the NPR of whom 4,236 were eligible for participation and 2,613 (62%) responded. Overall, the respondents covered the broad spectrum of MPN patients, but patients 70–79 years old, living with someone, of a Danish/Western ethnicity, and with a higher level of education exhibited the highest response rate.ConclusionA nationwide, population-based, and comprehensive HRQoL survey of MPN patients in Denmark was undertaken (MPNhealthSurvey). We believe that the respondents broadly represent the MPN population in Denmark. However, the differences between respondents and nonrespondents have to be taken into consideration when examining PROs from the respondents. The results of the investigation of the respondents’ HRQoL in this survey will follow in future articles.

show abstract

Chronic myeloid leukemia in the Netherlands: a population‐based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012

Abstract: This study gives insight into CML incidence, treatment, and survival in routine care in the Netherlands. Although OS improved since the introduction of TKIs, there is still room for further improvement.

Cited by 36 publications

References 32 publications

The impact of socio‐economic factors on treatment choice and mortality in chronic myeloid leukaemia

The impact of socio‐economic factors on treatment choice and mortality in chronic myeloid leukaemia

Long-term survival with CML with imatinib or transplantation as first-line treatment: Comparison of outcomes from CML Studies IIIA and IV

A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents

Contact Info

Product

Resources

About